250 related articles for article (PubMed ID: 15801270)
21. Circulating Sézary cells. A new preparatory method for their identification and enumeration.
Fletcher V; Zackheim HS; Beckstead JH
Arch Pathol Lab Med; 1984 Dec; 108(12):954-8. PubMed ID: 6239604
[TBL] [Abstract][Full Text] [Related]
22. Bilateral breast involvement in Sézary syndrome.
Balci P; Undar B; Yilmaz E; Seçil M; Ozsan H; Canda T
Eur Radiol; 2001; 11(12):2468-71. PubMed ID: 11734942
[TBL] [Abstract][Full Text] [Related]
23. Sezary syndrome: a case report and a review of the molecular pathomechanism and management.
Ng PP; Goh CL
Ann Acad Med Singap; 1998 Nov; 27(6):864-7. PubMed ID: 10101566
[TBL] [Abstract][Full Text] [Related]
24. Breast: Sezary Syndrome: A Unique Presentation.
Bedayat A; Mirzabeigi M; Yu H; Hultman R; MacMaster S
Breast J; 2015; 21(4):423-7. PubMed ID: 25939954
[TBL] [Abstract][Full Text] [Related]
25. Lymph node involvement by mycosis fungoides and Sézary syndrome mimicking angioimmunoblastic T-cell lymphoma.
LeBlanc RE; Lefterova MI; Suarez CJ; Tavallaee M; Kim YH; Schrijver I; Kim J; Gratzinger D
Hum Pathol; 2015 Sep; 46(9):1382-9. PubMed ID: 26193796
[TBL] [Abstract][Full Text] [Related]
26. Expression of CD164 on Malignant T cells in Sézary Syndrome.
Guenova E; Ignatova D; Chang YT; Contassot E; Mehra T; Saulite I; Navarini AA; Mitev V; Dummer R; Kazakov DV; French LE; Hoetzenecker W; Cozzio A
Acta Derm Venereol; 2016 May; 96(4):464-7. PubMed ID: 26524186
[TBL] [Abstract][Full Text] [Related]
27. Sarcoidal tissue reaction in Sézary syndrome.
Gregg PJ; Kantor GR; Telang GH; Lessin SR; Nowell PC; Vonderheid EC
J Am Acad Dermatol; 2000 Aug; 43(2 Pt 2):372-6. PubMed ID: 10901727
[TBL] [Abstract][Full Text] [Related]
28. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
[TBL] [Abstract][Full Text] [Related]
29. Neurolymphomatosis associated with Sézary syndrome.
Bezier M; Reguiaï Z; Delaby P; Laroche L; Saïd G; Bernard P; Grange F
Arch Dermatol; 2009 Mar; 145(3):294-6. PubMed ID: 19289760
[TBL] [Abstract][Full Text] [Related]
30. Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.
Scarisbrick JJ; Hodak E; Bagot M; Stranzenbach R; Stadler R; Ortiz-Romero PL; Papadavid E; Evison F; Knobler R; Quaglino P; Vermeer MH
Eur J Cancer; 2018 Apr; 93():47-56. PubMed ID: 29477101
[TBL] [Abstract][Full Text] [Related]
31. Adult T-cell leukemia/lymphoma clinically confused with viral/drug skin eruptions and pathologically misinterpreted as mycosis fungoides/Sézary syndrome.
AbdullGaffar B; Abdulrahman S
J Cutan Pathol; 2021 Sep; 48(9):1103-1108. PubMed ID: 33354782
[TBL] [Abstract][Full Text] [Related]
32. [T-cell prolymphocytic leukemia: potential diagnostic pitfalls].
Dessart P; Lemaire P; Le Dû K; Sandrini J; Prophette B; Maillard H
Ann Dermatol Venereol; 2014 Dec; 141(12):777-81. PubMed ID: 25433931
[TBL] [Abstract][Full Text] [Related]
33. Drug-induced pseudo-Sezary syndrome: a case report and literature review.
Reeder MJ; Wood GS
Am J Dermatopathol; 2015 Jan; 37(1):83-6. PubMed ID: 25033012
[TBL] [Abstract][Full Text] [Related]
34. Sézary syndrome without erythroderma.
Henn A; Michel L; Fite C; Deschamps L; Ortonne N; Ingen-Housz-Oro S; Marinho E; Beylot-Barry M; Bagot M; Laroche L; Crickx B; Maubec E
J Am Acad Dermatol; 2015 Jun; 72(6):1003-9.e1. PubMed ID: 25981000
[TBL] [Abstract][Full Text] [Related]
35. [CD30 positive pilotropic lymphoma].
Trémeau-Martinage C; Gorguet B; Lamant L; Brousset P; Loche F; Fillola G; Corberand J; Tkaczuck J; Bazex J
Ann Dermatol Venereol; 1999 May; 126(5):434-8. PubMed ID: 10434108
[TBL] [Abstract][Full Text] [Related]
36. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
Sausville EA; Eddy JL; Makuch RW; Fischmann AB; Schechter GP; Matthews M; Glatstein E; Ihde DC; Kaye F; Veach SR
Ann Intern Med; 1988 Sep; 109(5):372-82. PubMed ID: 3408055
[TBL] [Abstract][Full Text] [Related]
37. Sézary syndrome: diagnostic criteria and therapeutic options.
Russell-Jones R; Whittaker S
Semin Cutan Med Surg; 2000 Jun; 19(2):100-8. PubMed ID: 10892711
[TBL] [Abstract][Full Text] [Related]
38. [A patient with erythroderma and pruritus: Sézary syndrome].
Overweel AFP; Langerak AW; Damman J; de Haas ELM; Weerkamp F; Sandberg Y
Ned Tijdschr Geneeskd; 2022 Feb; 166():. PubMed ID: 35499588
[TBL] [Abstract][Full Text] [Related]
39. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
40. The Sézary syndrome: hematologic criteria.
Vonderheid EC; Bernengo MG
Hematol Oncol Clin North Am; 2003 Dec; 17(6):1367-89, viii. PubMed ID: 14710890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
